Blog
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
— Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
Terminates AG013 Oral Mucositis Development Program TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or “the Company”) today provided an update on progress with its SARS-CoV-2
Medidata Partners With CTI for Remote Source Review of Clinical Trials in Response to COVID-19
Medidata, the global leader in creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that CTI Clinical Trial
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
TARRYTOWN, N.Y., July 7, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure
PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
Hoth has exclusive license to this novel peptide COVID-19 therapeutic NEW YORK, June 30, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into
LabCorp Introduces Xcellerate® COVID-19 Clinical Study Solution
Advanced Analytics and Visualizations Empower Study Teams to Respond to Dynamic Environment, Manage Risk, Resume Studies and Safeguard Patients BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp (NYSE: LH), a
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology VICTORIA, BC, June 29, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”
Health ministry recommends use of Dexamethasone drug for COVID-19 patients
Dexamethasone drug has been tested in hospitalised patients with COVID-19 in the RECOVERY clinical trial and was found to have benefits for critically ill patients